Bioquarks promotes Spinal Cord Regeneration through Advanced Life Sciences

By CIOReview | Friday, January 8, 2016

FREMONT, CA: Bioquark in its latest move has collaborated with Revita Life Sciences to enhance the restoration function in spinal cord injury (SCI). The healthcare service provider, Bioquark primarily focuses on modernizing the natural biologic based products, services and technologies. The company works at countering wide range of diseases as well as complex regeneration.

On the other hand, Revita Life Sciences is a biotechnological company emphasizing on stem cell therapy. The company develops novel MRI based classification of spinal cord injuries and comprehensive treatment protocols.

“We look forward to working closely with Bioquark Inc. on this exciting initiative. The ability to merge cellular and biologic approaches represents the next evolutionary step in achieving complete regeneration and return of full functionality in this devastating disease,” said Dr. Himanshu Bansal, Managing Director, Revita Life Science.SCI injury is mainly caused by trauma that damages the spinal cord and leads to affect it either permanently or temporarily. In addition, the injury deteriorates the body functioning, and progressively hampers its movement and the strength. Furthermore, SCI depreciates the psychological, social and physical well being of an individual.

Bioquark’s treatment procedure includes prostheses and medications that promotes nerve cell regeneration and improves the functioning of the nerves .It also treats the damages of nerve cells and decreases inflammation near the site of injury. It is facilitated within eight hours of injury to enhance mild improvement.

“We are very excited about this collaboration with Revita Life Sciences. The natural synergy of our cellular and biologic to applications of regenerative medicine makes for novel and transformational opportunities in spinal cord injury resolution,” Says Ira S. Pastor, CEO, Bioquark. “